Drug Trial Radar · NCT06603142
Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
636
Planned (sponsor's estimate)
Start
Apr 22, 2024
Primary completion
Apr 2026
Study completion Apr 2026
Sponsor
- Lead sponsor
- Guangzhou Ruianbo Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of AR882 Capsules in patients with primary gout and hyperuricemia. The main questions it aims to answer are: What is the efficacy of AR882 Capsules in reducing serum uric acid levels in patients with primary gout and hyperuricemia? Researchers will compare AR882 Capsules with Febuxostat Tablets to see : Phase II: To explore the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia, aiming to determine the dosing regimen for the Phase III study Phase III: To evaluate the efficacy of AR882 Capsules in patients with primary gout and hyperuricemia. Participants will: Be randomly assigned to receive either AR882 Capsules or Febuxostat Tablets. Undergo regular assessments of serum uric acid levels. Report any adverse events or side effects experienced during the study.
Conditions
- Primary Gout
- Hyperuricemia
Interventions
Febuxostat 20MG TabletsDrug
Febuxostat 20MG Tablets
Febuxostat 20MG PlaceboDrug
Febuxostat 20MG Placebo
AR882 25MGDrug
AR882 25 MG Capsules
AR882 12.5MGDrug
AR882 12.5 MG Capsules
AR882 25MG PlaceboDrug
AR882 25MG Placebo
AR882 12.5MG PlaceboDrug
AR882 12.5MG Placebo
Febuxostat 40MG TabletsDrug
Febuxostat 40MG Tablets
Febuxostat 40MG PlaceboDrug
Febuxostat 40MG Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of participants with serum uric acid <360 μmol/LTime frame: 8 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Science
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.